全文获取类型
收费全文 | 10045篇 |
免费 | 1092篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 119篇 |
儿科学 | 264篇 |
妇产科学 | 189篇 |
基础医学 | 1172篇 |
口腔科学 | 547篇 |
临床医学 | 1255篇 |
内科学 | 1857篇 |
皮肤病学 | 99篇 |
神经病学 | 929篇 |
特种医学 | 279篇 |
外科学 | 1608篇 |
综合类 | 182篇 |
一般理论 | 11篇 |
预防医学 | 1169篇 |
眼科学 | 177篇 |
药学 | 497篇 |
中国医学 | 9篇 |
肿瘤学 | 808篇 |
出版年
2023年 | 126篇 |
2022年 | 172篇 |
2021年 | 330篇 |
2020年 | 266篇 |
2019年 | 372篇 |
2018年 | 392篇 |
2017年 | 304篇 |
2016年 | 300篇 |
2015年 | 291篇 |
2014年 | 447篇 |
2013年 | 529篇 |
2012年 | 764篇 |
2011年 | 770篇 |
2010年 | 430篇 |
2009年 | 323篇 |
2008年 | 566篇 |
2007年 | 588篇 |
2006年 | 458篇 |
2005年 | 452篇 |
2004年 | 389篇 |
2003年 | 339篇 |
2002年 | 312篇 |
2001年 | 210篇 |
2000年 | 218篇 |
1999年 | 179篇 |
1998年 | 86篇 |
1997年 | 65篇 |
1996年 | 50篇 |
1995年 | 61篇 |
1994年 | 49篇 |
1993年 | 32篇 |
1992年 | 109篇 |
1991年 | 115篇 |
1990年 | 82篇 |
1989年 | 69篇 |
1988年 | 81篇 |
1987年 | 100篇 |
1986年 | 66篇 |
1985年 | 72篇 |
1984年 | 56篇 |
1983年 | 59篇 |
1982年 | 34篇 |
1981年 | 40篇 |
1980年 | 35篇 |
1979年 | 51篇 |
1978年 | 48篇 |
1977年 | 27篇 |
1974年 | 28篇 |
1973年 | 45篇 |
1972年 | 26篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Victoria L. Parker Matthew C. Winter John A. Tidy Barry W. Hancock Julia E. Palmer Naveed Sarwar Baljeet Kaur Katie McDonald Xianne Aguiar Kamaljit Singh Nick Unsworth Imran Jabbar Allan A. Pacey Robert F. Harrison Michael J. Seckl 《International journal of cancer. Journal international du cancer》2023,152(5):986-997
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus. 相似文献
2.
3.
4.
5.
O.R. Mitchell R. Dave J. Bekker P.A. Brennan 《The British journal of oral & maxillofacial surgery》2021,59(3):384-385
The first COVID-19 vaccination was given in December 2020 and there is an effort to vaccinate the international population on a massive scale. Common side effects from the vaccine include headache and tiredness. Regional lymphadenopathy has been described in relation to other vaccines. We describe two cases of supraclavicular reactive lymphadenopathy presenting in patients who had the COVID vaccination in the ipsilateral arm. Awareness of this diagnosis is important for patients presenting to the neck lump clinic. 相似文献
6.
7.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
8.
9.
10.
Thaís dos Santos Fontes Pereira Carolina Cavalieri Gomes Peter A Brennan Felipe Paiva Fonseca Ricardo Santiago Gomez 《Journal of oral pathology & medicine》2019,48(1):3-9
Fibrous dysplasia is a non‐neoplastic developmental process that affects the craniofacial bones, characterized by painless enlargement as a result of bone substitution by abnormal fibrous tissue. Postzygotic somatic activating mutations in the GNAS1 gene cause fibrous dysplasia and have been extensively investigated, as well as being helpful in the differential diagnosis of the disease. Fibrous dysplasia may involve one (monostotic) or multiple bones (polyostotic), sporadically or in association with McCune‐Albright syndrome, Jeffe‐Lichenstein syndrome, or Mazabreud syndrome. This review summarizes the current knowledge on fibrous dysplasia, emphasizing the value of integrating the understanding of its molecular pathogenesis with the clinical, radiological, and histopathological features. In addition, we address important aspects related to the differential diagnosis and patient management. 相似文献